Palm Beach Gardens Medical Center 1st Hospital in Palm Beach County to Use New Impella 5.5 Technology to Enable Better Heart Recovery for Heart Attack Patients

September 14, 2020

Palm Beach Gardens Medical Center is the first hospital in Palm Beach County to perform a heart procedure with the Impella 5.5™ with Smart Assist®, a new technology to enable heart recovery in patients whose hearts are too weak to effectively pump blood on their own after a heart attack.

Dr Nishant PatelPalm Beach Gardens Medical center notes cardiothoracic surgeon, Dr. Nishant Patel, is the first surgeon at the hospital to use the device for a procedure.

The Impella 5.5 with SmartAssist is a heart pump that is temporarily implanted minimally invasively in a patient’s heart.  It reduces the heart’s workload and oxygen demand, which enables the heart to rest and recover, supply much needed blood and oxygen to the patient’s other vital organs, and allow patients the ability to walk just 24 hours following surgery.

“This advanced technology gives us a new and potentially better option to treat patients who are very sick due to a heart attack,” said Teresa Urquhart, chief executive officer for Palm Beach Gardens Medical Center. “It is a minimally-invasive treatment option that enables a patient’s heart to rest and ultimately recover, improving the patient’s long-term quality of life compared to other therapies. This new technology furthers our commitment to providing patients in Palm Beach County with comprehensive cardiovascular treatment options.”

Impella 5.5 with SmartAssist integrates data informatics including left ventricular pressure (LVP), end-diastolic pressure (EDP) and cardiac power output (CPO) that can help physicians make treatment decisions.  The SmartAssist fiberoptic pressure sensor allows for precise pump positioning, management and repositioning in the ICU.  The technology also includes Impella Connect, which enables medical providers to view the Impella control screen through a secure feed, and easily track and review cases.

“Palm Beach Gardens Medical Center is always a leading provider in cardiovascular care in Palm Beach County, and aims to provide the most advanced care to our patients,” said Dr. Nishant Patel, cardiothoracic surgeon for Palm Beach Gardens Medical Center. “Adding the Impella 5.5 with SmartAssist technology to our cardiovascular services means we can provide a new option to patients whose hearts are too weak to effectively pump blood on their own after a heart attack.  This gives severely ill patients the best chance to recover and return home with a good long-term quality of life.”

Impella 5.5 with SmartAssist is the newest Impella heart pump from Abiomed of Danvers, Massachusetts and is FDA approved as a therapy for cardiogenic shock for up to 14 days.  The Impella platform of technologies is the most studied mechanical circulatory support platform in the history of the FDA with real world clinical data on more than 100,000 patients and more than 550 peer-reviewed publications.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”